When it comes to CLL/SLL treatment, what’s the difference between BTK inhibitors and BCL-2 inhibitors? Understanding how these treatment approaches work and how they fit into the treatment…
BTK degrader BGB-16673 reduced tumor burden in 85% of patients from a high-risk, hard-to-treat group with relapsed / refractory CLL. Dr. Stephan Stilgenbauer from Ulm University and colleagues…
Dan H. Barouch, MD, PhD, the William Bosworth Castle Professor of Medicine at Harvard Medical School and director of the Center for Virology and Vaccine Research at Beth-Israel…
Samuel I. Fink, MD, FACP, internal medicine specialist in private practice in Tarzana, California, and his daughter, Sarrica Fink, RN, previously in practice at Cedar Sinai Medical Center…
Researchers from UC Davis and the University of Oregon have created a 3D model of how airflow in a restaurant dining room might influence the transmission of COVID-19…
In this interview, Shirish M. Gadgeel, MD, MBBS, medical oncologist at Michigan Medicine, University of Michigan, provides insights into multikinase tyrosine kinase inhibitor (TKI) treatments and their varied…
A study completed by researchers in China, of patients with renal cell carcinoma (RCC), attempted to both validate previous conclusions and look at the influencing factors of perioperative renal…
In this interview, David Polsky, MD, PhD, shares details about his advanced laboratory tumor detection technology and the study results presented at ASCO 2020. Dr. Polsky suggests that…
Rogerio C. Lilenbaum, MD, director of the Banner MD Anderson Cancer Center, discusses the ways physicians practicing in different care institutions order molecular panels for patients with nonsquamous…
Samuel I. Fink, MD, FACP, internal medicine specialist in private practice in Tarzana, California, and his daughter, Sarrica Fink, RN, previously in practice at Cedar Sinai Medical Center…
In this “Practice Pearls” webinar hosted by Pharmacy Times, expert panelists discuss important topics regarding the treatment of patients with acute myeloid leukemia (AML). Panelists: Katie Culos, PharmD,…
Rajneesh Nath, MD, medical oncologist at the Banner MD Anderson Cancer Center, discusses early results from the phase 3 SIERRA trial investigating the efficacy of Iomab-B and protocol-specified…
